Author: Steve Kopczak

LitAlert ~~ GeneLit.com

    • Overview of familial syndromes with increased skin malignancies.
    • Juan HY, Zhou AE, Hoegler KM, Khachemoune A.
    • Arch Dermatol Res. 2022 Nov 7. doi: 10.1007/s00403-022-02447-8. Epub ahead of print.
    • Review

    • Interdisciplinary risk counseling for hereditary breast and ovarian cancer: real-world data from a specialized center.
    • Zang B, Helms M, Besch L, Kalmbach N, Stegen S, Blohmer JU, Speiser D.
    • Arch Gynecol Obstet. 2022 Oct 28. doi: 10.1007/s00404-022-06819-3. Epub ahead of print.

    • Germline mutations in 5' to c.7914 of BRCA2 significantly increase risk of prostate cancer.
    • Ruan XH, Huang D, Lin XL, Fang ZJ, Ding Q, Wu YS, Na R.
    • Asian J Androl. 2022 Oct 28. doi: 10.4103/aja202277. Epub ahead of print.

    • Overlapping gene dependencies for PARP inhibitors and carboplatin response identified by functional CRISPR-Cas9 screening in ovarian cancer.
    • Coelho R, Tozzi A, Disler M, Lombardo F, Fedier A, López MN, Freuler F, Jacob F, Heinzelmann-Schwarz V.
    • Cell Death Dis. 2022 Oct 28;13(10):909. doi: 10.1038/s41419-022-05347-x.

    • Nonsurgical Options for Risk Reduction of Contralateral Breast Cancer in BRCA Mutation Carriers With Early-Stage Breast Cancer.
    • Evron E, Ben-David MA, Kaidar-Person O, Corn BW.
    • J Clin Oncol. 2022 Oct 28:JCO2201609. doi: 10.1200/JCO.22.01609. Epub ahead of print.

    • Optimizing Therapy for Ovarian Cancer: Recent Data Highlights - Episode 7: Novel Maintenance Strategies Being Explored in Advanced Ovarian Cancer Treatment.
    • Monk BJ, Coleman RL, Westin SN, Birrer MJ.
    • OncLive. Peer Exchange. 2022 Oct 27.

    • Optimizing Therapy for Ovarian Cancer: Recent Data Highlights - Episode 8: PARP Inhibitor Resistance in Ovarian Cancer Treatment.
    • Monk BJ, Coleman RL, Westin SN, Birrer MJ.
    • OncLive. Peer Exchange. 2022 Oct 27.

    • Safety and efficacy of avelumab plus carboplatin in patients with metastatic castration-resistant prostate cancer in an open-label Phase Ib study.
    • Rodriguez-Vida A, Maroto P, Font A, Martin C, Mellado B, Corbera A, Orrillo M, Reig O, Querol R, Rios-Hoyo A, Cano L, Alonso J, Martinez G, Galtes S, Taus A, Martinez-Garcia M, Juanpere N, Juan O, Bellmunt J.
    • Br J Cancer. 2022 Oct 26. doi: 10.1038/s41416-022-01991-4. Epub ahead of print.

    • Common germline risk variants impact somatic alterations and clinical features across cancers.
    • Namba S, Saito Y, Kogure Y, Masuda T, Bondy ML, Gharahkhani P, Gockel I, Heider D, Hillmer A, Jankowski J, MacGregor S, Maj C, Melin B, Ostrom QT, Palles C, Schumacher J, Tomlinson I, Whiteman DC, Okada Y, Kataoka K.
    • Cancer Res. 2022 Oct 26:CAN-22-1492. doi: 10.1158/0008-5472.CAN-22-1492. Epub ahead of print.

    • TRAIL Receptor Targeting Agents Potentiate PARP Inhibitor Efficacy in Pancreatic Cancer Independently of BRCA2 Mutation Status.
    • Khaled NB, Hammer K, Ye L, Alnatsha A, Widholz SA, Piseddu I, Sirtl S, Schneider J, Munker S, Mahajan UM, Montero JJ, Griger J, Mayerle J, Reiter FP, De Toni EN.
    • Cancers (Basel). 2022 Oct 26;14(21):5240. doi: 10.3390/cancers14215240.

    • Olaparib as a single agent treatment in pre-treated metastatic pancreatic cancer patient harboring BRCA2 mutation: What could we expect?
    • Garajová I, Balsano R, Gelsomino F, Leonardi F.
    • Tumori. 2022 Oct 26:3008916221132589. doi: 10.1177/03008916221132589. Epub ahead of print.
    • Case report

    • Efficacy and safety of Gemogenovatucel-T (Vigil) immunotherapy for advanced ovarian carcinoma: A systematic review and meta-analysis of randomized controlled trials.
    • Zhang Y, Zhang L, Zhao Y, Wang S, Feng L.
    • Front Oncol. 2022 Oct 21;12:945867. doi: 10.3389/fonc.2022.945867.

    Related:

    •• Review registration number: CRD42022300367: Efficacy and safety of Gemogenovatucel-T (Vigil) immunotherapy for advanced ovarian cancer: A systematic review and meta-analysis of randomized controlled trials. (PROSPERO register. Accessed 2022 Nov 7.)

    • Risk reduction and screening of cancer in hereditary breast-ovarian cancer syndromes: ESMO Clinical Practice Guideline.
    • Sessa C, Balmaña J, Bober SL, Cardoso MJ, Colombo N, Curigliano G, Domchek SM, Evans DG, Fischerova D, Harbeck N, Kuhl C, Lemley B, Levy-Lahad E, Lambertini M, Ledermann JA, Loibl S, Phillips KA, Shimon P; ESMO Guidelines Committee.
    • Ann Oncol. 2022 Oct 19:S0923-7534(22)04193-X. doi: 10.1016/j.annonc.2022.10.004. Epub ahead of print.

    • LitAlert ~~ GeneLit.com

    • Overview of familial syndromes with increased skin malignancies.
    • Juan HY, Zhou AE, Hoegler KM, Khachemoune A.
    • Arch Dermatol Res. 2022 Nov 7. doi: 10.1007/s00403-022-02447-8. Epub ahead of print.
    • Review

    • Interdisciplinary risk counseling for hereditary breast and ovarian cancer: real-world data from a specialized center.
    • Zang B, Helms M, Besch L, Kalmbach N, Stegen S, Blohmer JU, Speiser D.
    • Arch Gynecol Obstet. 2022 Oct 28. doi: 10.1007/s00404-022-06819-3. Epub ahead of print.

    • Germline mutations in 5' to c.7914 of BRCA2 significantly increase risk of prostate cancer.
    • Ruan XH, Huang D, Lin XL, Fang ZJ, Ding Q, Wu YS, Na R.
    • Asian J Androl. 2022 Oct 28. doi: 10.4103/aja202277. Epub ahead of print.

    • Safety and efficacy of avelumab plus carboplatin in patients with metastatic castration-resistant prostate cancer in an open-label Phase Ib study.
    • Rodriguez-Vida A, Maroto P, Font A, Martin C, Mellado B, Corbera A, Orrillo M, Reig O, Querol R, Rios-Hoyo A, Cano L, Alonso J, Martinez G, Galtes S, Taus A, Martinez-Garcia M, Juanpere N, Juan O, Bellmunt J.
    • Br J Cancer. 2022 Oct 26. doi: 10.1038/s41416-022-01991-4. Epub ahead of print.

    • Common germline risk variants impact somatic alterations and clinical features across cancers.
    • Namba S, Saito Y, Kogure Y, Masuda T, Bondy ML, Gharahkhani P, Gockel I, Heider D, Hillmer A, Jankowski J, MacGregor S, Maj C, Melin B, Ostrom QT, Palles C, Schumacher J, Tomlinson I, Whiteman DC, Okada Y, Kataoka K.
    • Cancer Res. 2022 Oct 26:CAN-22-1492. doi: 10.1158/0008-5472.CAN-22-1492. Epub ahead of print.

    • Hereditary Breast and Ovarian Cancer Service in Sparsely Populated Western Pomerania.
    • Felbor U, Bülow R, Schmutzler RK, Rath M.
    • Healthcare (Basel). 2022 Oct 13;10(10):2021. doi: 10.3390/healthcare10102021.

    • Application of Multigene Panels Testing for Hereditary Cancer Syndromes.
    • Bilyalov A, Nikolaev S, Shigapova L, Khatkov I, Danishevich A, Zhukova L, Smolin S, Titova M, Lisica T, Bodunova N, Shagimardanova E, Gusev O.
    • Biology (Basel). 2022 Oct 5;11(10):1461. doi: 10.3390/biology11101461.

    • LitAlert ~~ GeneLit.com

    • Overview of familial syndromes with increased skin malignancies.
    • Juan HY, Zhou AE, Hoegler KM, Khachemoune A.
    • Arch Dermatol Res. 2022 Nov 7. doi: 10.1007/s00403-022-02447-8. Epub ahead of print.
    • Review

    • Thermo Fisher Introduces Homologous Recombination Deficiency Score for Cancer Profiling Assay.
    • Han AP.
    • GenomeWeb. 2022 Nov 7.
    • News

    • Loss of Heterozygosity of BRCA1/2 as a Predictive Marker for Talazoparib Response.
    • Mizrahi AG, Hamad H, Gugenheim A, Nisman B, Kuznetz A, David IB, Gelfend Y, Cohen S, Zick A, Sheva K, Nechushtan H, Peretz T, Meirovitz A.
    • Anticancer Res. 2022 Nov;42(11):5257-5263. doi: 10.21873/anticanres.16032.

    • Efficacy and safety of Gemogenovatucel-T (Vigil) immunotherapy for advanced ovarian carcinoma: A systematic review and meta-analysis of randomized controlled trials.
    • Zhang Y, Zhang L, Zhao Y, Wang S, Feng L.
    • Front Oncol. 2022 Oct 21;12:945867. doi: 10.3389/fonc.2022.945867.

    Related:

    •• Review registration number: CRD42022300367: Efficacy and safety of Gemogenovatucel-T (Vigil) immunotherapy for advanced ovarian cancer: A systematic review and meta-analysis of randomized controlled trials. (PROSPERO register. Accessed 2022 Nov 7.)

    • Risk reduction and screening of cancer in hereditary breast-ovarian cancer syndromes: ESMO Clinical Practice Guideline.
    • Sessa C, Balmaña J, Bober SL, Cardoso MJ, Colombo N, Curigliano G, Domchek SM, Evans DG, Fischerova D, Harbeck N, Kuhl C, Lemley B, Levy-Lahad E, Lambertini M, Ledermann JA, Loibl S, Phillips KA, Shimon P; ESMO Guidelines Committee.
    • Ann Oncol. 2022 Oct 19:S0923-7534(22)04193-X. doi: 10.1016/j.annonc.2022.10.004. Epub ahead of print.

    • Interdisciplinary risk counseling for hereditary breast and ovarian cancer: real-world data from a specialized center.
    • Zang B, Helms M, Besch L, Kalmbach N, Stegen S, Blohmer JU, Speiser D.
    • Arch Gynecol Obstet. 2022 Oct 28. doi: 10.1007/s00404-022-06819-3. Epub ahead of print.

    • LitAlert ~~ GeneLit.com

    • Hereditary Breast and Ovarian Cancer Service in Sparsely Populated Western Pomerania.
    • Felbor U, Bülow R, Schmutzler RK, Rath M.
    • Healthcare (Basel). 2022 Oct 13;10(10):2021. doi: 10.3390/healthcare10102021.

    • Application of Multigene Panels Testing for Hereditary Cancer Syndromes.
    • Bilyalov A, Nikolaev S, Shigapova L, Khatkov I, Danishevich A, Zhukova L, Smolin S, Titova M, Lisica T, Bodunova N, Shagimardanova E, Gusev O.
    • Biology (Basel). 2022 Oct 5;11(10):1461. doi: 10.3390/biology11101461.

    • LitAlert ~~ GeneLit.com

    • Thermo Fisher Introduces Homologous Recombination Deficiency Score for Cancer Profiling Assay.
    • Han AP.
    • GenomeWeb. 2022 Nov 7.
    • News

    • Loss of Heterozygosity of BRCA1/2 as a Predictive Marker for Talazoparib Response.
    • Mizrahi AG, Hamad H, Gugenheim A, Nisman B, Kuznetz A, David IB, Gelfend Y, Cohen S, Zick A, Sheva K, Nechushtan H, Peretz T, Meirovitz A.
    • Anticancer Res. 2022 Nov;42(11):5257-5263. doi: 10.21873/anticanres.16032.

    • Revision Rate of Direct-to-Implant Breast Reconstruction: Is it Truly a Single-Stage Reconstruction? A Single-Surgeon Experience.
    • Adler N, Carmon E, Houri P.
    • Aesthetic Plast Surg. 2022 Oct 28. doi: 10.1007/s00266-022-03136-7. Epub ahead of print.

    • Overlapping gene dependencies for PARP inhibitors and carboplatin response identified by functional CRISPR-Cas9 screening in ovarian cancer.
    • Coelho R, Tozzi A, Disler M, Lombardo F, Fedier A, López MN, Freuler F, Jacob F, Heinzelmann-Schwarz V.
    • Cell Death Dis. 2022 Oct 28;13(10):909. doi: 10.1038/s41419-022-05347-x.

    • Nonsurgical Options for Risk Reduction of Contralateral Breast Cancer in BRCA Mutation Carriers With Early-Stage Breast Cancer.
    • Evron E, Ben-David MA, Kaidar-Person O, Corn BW.
    • J Clin Oncol. 2022 Oct 28:JCO2201609. doi: 10.1200/JCO.22.01609. Epub ahead of print.

    • Optimizing Therapy for Ovarian Cancer: Recent Data Highlights - Episode 7: Novel Maintenance Strategies Being Explored in Advanced Ovarian Cancer Treatment.
    • Monk BJ, Coleman RL, Westin SN, Birrer MJ.
    • OncLive. Peer Exchange. 2022 Oct 27.

    • Optimizing Therapy for Ovarian Cancer: Recent Data Highlights - Episode 8: PARP Inhibitor Resistance in Ovarian Cancer Treatment.
    • Monk BJ, Coleman RL, Westin SN, Birrer MJ.
    • OncLive. Peer Exchange. 2022 Oct 27.

    • Safety and efficacy of avelumab plus carboplatin in patients with metastatic castration-resistant prostate cancer in an open-label Phase Ib study.
    • Rodriguez-Vida A, Maroto P, Font A, Martin C, Mellado B, Corbera A, Orrillo M, Reig O, Querol R, Rios-Hoyo A, Cano L, Alonso J, Martinez G, Galtes S, Taus A, Martinez-Garcia M, Juanpere N, Juan O, Bellmunt J.
    • Br J Cancer. 2022 Oct 26. doi: 10.1038/s41416-022-01991-4. Epub ahead of print.

    • TRAIL Receptor Targeting Agents Potentiate PARP Inhibitor Efficacy in Pancreatic Cancer Independently of BRCA2 Mutation Status.
    • Khaled NB, Hammer K, Ye L, Alnatsha A, Widholz SA, Piseddu I, Sirtl S, Schneider J, Munker S, Mahajan UM, Montero JJ, Griger J, Mayerle J, Reiter FP, De Toni EN.
    • Cancers (Basel). 2022 Oct 26;14(21):5240. doi: 10.3390/cancers14215240.

    • Olaparib as a single agent treatment in pre-treated metastatic pancreatic cancer patient harboring BRCA2 mutation: What could we expect?
    • Garajová I, Balsano R, Gelsomino F, Leonardi F.
    • Tumori. 2022 Oct 26:3008916221132589. doi: 10.1177/03008916221132589. Epub ahead of print.
    • Case report

    • Efficacy and safety of Gemogenovatucel-T (Vigil) immunotherapy for advanced ovarian carcinoma: A systematic review and meta-analysis of randomized controlled trials.
    • Zhang Y, Zhang L, Zhao Y, Wang S, Feng L.
    • Front Oncol. 2022 Oct 21;12:945867. doi: 10.3389/fonc.2022.945867.

    Related:

    •• Review registration number: CRD42022300367: Efficacy and safety of Gemogenovatucel-T (Vigil) immunotherapy for advanced ovarian cancer: A systematic review and meta-analysis of randomized controlled trials. (PROSPERO register. Accessed 2022 Nov 7.)

    • LitAlert ~~ GeneLit.com

    • Library adaptors with integrated reference controls improve the accuracy and reliability of nanopore sequencing.
    • Gunter HM, Youlten SE, Madala BS, Reis ALM, Stevanovski I, Wong T, Kummerfield SK, Deveson IW, Santini NS, Marcellin E, Mercer TR.
    • Nat Commun. 2022 Oct 28;13(1):6437. doi: 10.1038/s41467-022-34028-8.

    • Electrochemical biosensors for analysis of DNA point mutations in cancer research.
    • Ondraskova K, Sebuyoya R, Moranova L, Holcakova J, Vonka P, Hrstka R, Bartosik M.
    • Anal Bioanal Chem. 2022 Oct 27. doi: 10.1007/s00216-022-04388-7. Epub ahead of print.
    • Review